Assignment: Immunization Presentation

Assignment: Immunization Presentation

Assignment: Immunization Presentation

Directions  For this Assignment you are creating a PowerPoint® presentation. Your presentation audience is the community. The topic is immunization/ vaccination. Information should include herd immunity, types of immunity related to vaccination, immunization effects on the individual, and community as well as worldwide effects of immunization. Additionally content should include vaccination trends, myths, disease statistics for those conditions prevented with vaccination, and pediatric vaccination schedule/s. Legal, ethical, and cultural considerations should be addressed. The presentation must have speaker notes per slide; 1–3 paragraphs. The PowerPoint should be developed in a professional design and style; succinct, not overly wordy, with a tasteful amount of elegant text and visual appeal, as well as accurate and complete content.Number of content slides are 12, not to exceed 14. Title slide and reference slide required and not included in the total. This presentation should adhere to appropriate 6th edition APA format.  Number of content slides are 12, not to exceed 14. Title slide and reference slide required and not included in the total. This presentation should adhere to appropriate 6th edition APA format.

The process of exposing the body to an antigen in order to produce an adaptive immune response takes days/weeks to mature, but the response can endure a long time—even a lifetime. 

Similarly, administering two doses of hepatitis A vaccination results in an acquired active immune response that provides long-term (potentially permanent) protection. Because the hepatitis A vaccination has only been available since the late 1980s, follow-up studies of duration of protection have been limited to 25 years—hence the disclaimer concerning duration of protection mentioned earlier.

The transfer of maternal tetanus antibody (mostly IgG) across the placenta offers natural passive protection to the newborn for several weeks/months until the antibody is destroyed and lost. 

I Bio Products Laboratory: Human Hepatitis B Immunoglobulin Ph.Eur.* Human hepatitis B immunoglobulin is available in 200 and 500 IU vial sizes. 

(ii) Bio Products Laboratory: Human Rabies Immunoglobulin Ph.Eur.* 

Each millilitre contains 40–180 mg/ml human protein, with gammaglobulins accounting for at least 95% of the total (IgG). 

It is given as part of post-exposure prophylaxis to non-immune people who have been exposed to rabies.

A 250 IU vial of human tetanus immunoglobulin is available. Each millilitre contains 40–180 mg/ml human protein, with gammaglobulins accounting for at least 95% of the total (IgG). This product is made with plasma from vetted donors in the United States. 

This preparation is unlikely to be used by health-care providers; it is given as part of the management of tetanus-prone wounds with substantial soil/manure contamination and as part of the management of all wounds if the individual is suspected of being non-immune.

Each vial contains 250 mg protein (40–180 mg/ml), with gammaglobulins accounting for at least 95% of the total (IgG). This product is made with plasma from vetted donors in the United States. 

It is administered to non-immune people who have been exposed to chickenpox as part of their post-exposure prophylaxis.